Glaxosmithkline’s chief executive said that it was vital to bring new medicines to the market over the next few years GSKEmma Walmsley has put a shake-up of drug development at Glaxosmithkline at the heart of her leadership as she set about addressing investors’ concerns over the group’s lacklustre research productivity. Addressing the City for the first time, the newly appointed chief executive of Britain’s biggest pharmaceutical company demanded bigger returns from research and development, fewer and larger drug launches and called for commercial influences earlier in the science process. “The clear priority here will be making the right choices to develop our pharma pipeline, which is promising but unproven,” she said. “We have a lot of work to do here and we need to make sure that our R&D and commercial organisations are partnering really effectively together.”The renewed scrutiny of Glaxo’s core pharma division…

Source: The Times April 26, 2017 16:07 UTC